<qa>  What is the EVALUATION OF ALIROCUMAB IN ADDITION TOEVALUATION OF ALIROCUMAB IN ADDITION TO LIPID-MODIFYING THERAPY IN PATIENTS WITH HIGH CARDIOVASCULAR RISK AND HYPERCHOLESTEROLEMIA IN SOUTH KOREA AND TAIWAN: 